超声

Search documents
秉持创新理念,北芯生命为心血管精准介入领域发展献力
Sou Hu Wang· 2025-07-12 09:00
Group 1 - Shenzhen Beixin Life Technology Co., Ltd. focuses on cardiovascular precision intervention solutions, addressing urgent clinical needs and competing with international innovative products [1] - The company has achieved significant milestones, including the first approved FFR system and the first domestically developed 60MHz IVUS system in China, filling gaps in domestic offerings [1] - Beixin Life has established a comprehensive chain for the independent research, production, and commercialization of high-end active interventional devices and consumables, achieving process localization and international quality standards [1] Group 2 - Beixin Life has received multiple recognitions, including being named a national "Little Giant" enterprise and a high-tech enterprise, with an increasing export share of high-end Class III medical devices [2] - The FFR system received EU MDD certification in March 2020, and the IVUS system is expected to receive EU MDR certification in May 2024, showcasing the company's innovation in medical devices [2] - The company has obtained over 20 Class III medical device registrations and more than 80 authorized invention patents, serving over 1,500 hospitals in more than 50 countries [2] Group 3 - Beixin Life was recognized in the "2024 Chuangyebang 100 Future Unicorn" list, highlighting its innovation capabilities and growth prospects in the high-performance medical device sector [3] - The company aims to continue its leadership in intelligent cardiovascular precision intervention solutions, enhancing product quality and services to improve patient health globally [3] - Beixin Life is committed to fostering the global competitiveness of China's high-performance medical device industry [3]
6月河南医疗器械招采市场分析:招标预算总额11.46亿元,商丘中标总额居首位
Sou Hu Cai Jing· 2025-07-11 08:16
本月,招标项目数量与预算金额双双大幅攀升——招标项目环比上涨27.84%,招标预算总金额环比增 加7.46亿元,达到11.46亿元,其中预算超千万元的项目达30个,两家医院的招标预算突破亿元大关。中 标环节同样活跃,中标总金额达3.55亿元,商丘市以6647.9万元的中标总额超越郑州,领跑全省。 【大河财立方 记者 唐卫东】立方招采通显示,6月份,河南省累计开展医疗器械及相关服务招标和中标 项目共计725个。 招标预算环比增加7.46亿元 两家医院预算超1亿元 在招标环节,河南省招标数量环比上升27.84%,由370个升至473个,其中预算超1000万元的项目有30 个。招标预算总金额为11.46亿元,相较于5月份增加7.46亿元。 从地区看,郑州市以195个招标项目排在第1位,占河南省整体超40%,同时,郑州市以4.14亿元招标预 算总额领跑全省。相较于5月,郑州市招标项目在数量及金额方面均有所增加,其中招标预算总金额环 比增加3.27亿元,增幅超300%。 这是由于6月郑州市预算1000万元以上的大项目有11个,其中河南中医药大学第一附属医院高端影像设 备采购项目预算金额超过5000万元。而在5月,郑州市 ...
政策红利兑现!国产器械半年狂揽45项批文,恒生医疗ETF(513060)成创新升级"精准入口"
Sou Hu Cai Jing· 2025-07-11 02:36
今日生物医药、创新药、医药外包等大医药概念走强,药明合联涨超9%,药明康德AH股涨超9%,带 动恒生生物科技指数涨1.5%。 相关ETF方面,恒生医疗ETF(513060)早盘高开,盘中持续震荡,截至发稿,涨近1%,成交额近10亿 元,交投活跃。成分股中多数上涨,药明康德涨超8%;药明合联涨超7%;药明生物、固生堂、诺诚健 华涨超3%;先声药业、翰森制药、四环医药、微创机器人-B、微创医疗等个股跟涨,涨幅均超2%。 政策红利加速释放,产业迈入创新高速增长期 2025年上半年,中国创新医疗器械领域迎来里程碑式突破。国家药监局数据显示,上半年共批准45个创 新医疗器械产品上市,同比增长高达87%,增速创历史新高。同期创新药批准数量达43个,同比增长 59%,政策改革红利正加速转化为产业发展动能。这一爆发式增长背后,是药监部门出台的10项全生命 周期监管优化举措,覆盖审批加速、国际标准对接及临床应用支持等关键环节。在政策精准滴灌下,包 括心脏脉冲电场消融设备、血管内超声导管、三尖瓣修复系统在内的一批技术集成度高、研发难度大的 高端器械集中上市,标志着中国医疗器械产业正式迈入创新驱动的高质量发展周期。 国产高端化突破 ...
议程持续更新!读者福利!第二届全球医疗科技大会!
思宇MedTech· 2025-07-10 10:13
Core Points - The article announces the upcoming Second Global Medical Technology Conference scheduled for July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, expecting around 500 attendees [3][8] - The conference will feature various discussions on topics such as AI in medical devices, wearable brain-machine interfaces, and trends in the medical device industry for 2025 [4] Group 1 - The conference is organized by SYMedTech and the Zhongguancun Alliance for New Life Sciences [3] - Collaborating organizations include Qidi Star, He Yuan Technology Incubator, and Zhongguancun Science City CGT Industry Incubator [2] - The agenda includes presentations from industry experts on innovative medical technologies and investment strategies [4] Group 2 - The event will also include a roundtable discussion focusing on multi-modal data infrastructure and AI applications in medicine [4] - Other topics of discussion will cover the development of the pulsed electric field ablation industry and AI's role in reshaping brain health [4] - The article provides a registration link with a promotional offer for attendees [8]
半年盘点|上半年45个创新医疗器械获批,国产设备向高端化迈进
Di Yi Cai Jing· 2025-07-10 04:53
Core Insights - The integration of high-tech medical devices such as AI medical devices, medical robots, and implantable medical devices is crucial for shaping new productive forces in the medical device industry [1] - In the first half of this year, China approved 43 innovative drugs and 45 innovative medical devices, marking year-on-year growth of 59% and 87% respectively, indicating that reform policy dividends are transforming into industrial development momentum [1] - The approval of innovative medical devices has reached a new high, with the National Medical Products Administration (NMPA) introducing 10 measures to optimize lifecycle supervision and support the innovation of high-end medical devices [1] Medical Device Innovation - Domestic innovative medical device companies are increasingly emerging, with Shenzhen Beixin Life Technology's peripheral IVUS (intravascular ultrasound) catheter breaking the monopoly of imported products, marking a breakthrough in China's peripheral vascular precision intervention [3] - The introduction of IVUS technology allows for clearer visualization of vascular conditions, addressing limitations of traditional DSA (digital subtraction angiography) methods [3] - The application of IVUS in peripheral vascular intervention is still limited due to product usability issues and insufficient training [3] Market Competition in High-End Medical Devices - The competition in the high-end innovative medical device sector is intensifying, particularly in the field of cardiac pulsed field ablation (PFA), which has seen multiple domestic PFA products approved recently [5] - PFA technology is primarily used for atrial fibrillation treatment and is expected to benefit patients with difficult-to-treat conditions [5] - Major global players like Johnson & Johnson, Medtronic, Boston Scientific, and Abbott dominate over 85% of the electrophysiology market in China, while domestic companies are beginning to gain traction [5] Market Growth Projections - The Chinese cardiac electrophysiology surgery volume is expected to approach 500,000 cases by 2024, with the PFA market projected to reach 1.3 billion yuan by 2025 and grow to 16.3 billion yuan by 2032, reflecting a compound annual growth rate of 43.73% [6] Breakthroughs in Heart Valve Technology - The approval of Shanghai Huihe Medical's transcatheter tricuspid valve ring shaping system K-Clip marks the first domestic tricuspid valve medical device, filling a long-standing gap in the market [7] - There are over 1 million patients with severe tricuspid regurgitation in China, with nearly half potentially benefiting from new tricuspid valve devices [7] - The global market for tricuspid valve devices is expected to expand as more products receive regulatory approval [8] AI and Robotics in Healthcare - The integration of AI technology and robotics in healthcare is anticipated to create innovative opportunities, with the NMPA initiating a second batch of tasks for AI medical devices and biomedical materials [8] - AI models are empowering various aspects of the healthcare industry, from diagnostic assistance to personalized treatment plans and medical image analysis [9]
瑞康医药80后高管留置背后,10倍溢价收购疑云笼罩
Xin Lang Zheng Quan· 2025-07-10 02:41
Core Viewpoint - The simultaneous announcement of a share buyback and the detention of a senior executive at Ruikang Pharmaceutical has raised significant concerns in the capital market, particularly regarding a controversial related-party transaction that occurred six months prior [1]. Group 1: Controversial Acquisition - Ruikang Pharmaceutical announced the acquisition of 76.01% of Zhejiang Hengjiu Medical Equipment for 151 million yuan, despite the target company having zero revenue and a net loss of 6.81 million yuan in the first eight months of 2024 [2]. - The acquisition price represented a nearly 10-fold premium over the target company's net asset value of 18.22 million yuan, with an assessed value of 239.5 million yuan [2]. - The actual controller of the transaction counterpart, Yantai Hengyue, is linked to senior executives including Li Zhe, indicating a typical related-party transaction [2]. Group 2: Executive Detention and Background - Li Zhe, the detained executive, has a financial background with experience at major institutions and a relatively low annual salary of 403,500 yuan, yet he was deeply involved in the controversial acquisition [3]. - Li Zhe controls Yantai Hengyue through Hangzhou Huaheng Investment Management Co., and the acquisition included a three-year profit commitment of 56 million yuan from 2027 to 2029, despite the core product still being in the development stage [3]. Group 3: Financial Performance and Challenges - Ruikang Pharmaceutical has faced a dramatic decline in revenue, dropping from 27.23 billion yuan in 2020 to 7.966 billion yuan in 2024, a decrease of over 70% [4]. - The company has reported cumulative losses of 1.496 billion yuan from 2021 to 2024, with a further 44.75% decline in net profit in the first quarter of 2025 [4]. - Regulatory warnings have been frequent, with the company and its executives being recorded in integrity files for concealing 460 million yuan in related-party capital increases and financial support [4]. Group 4: Market Reactions and Future Outlook - As of June 30, Ruikang Pharmaceutical spent 60.39 million yuan to repurchase 20.44 million shares in an attempt to instill confidence in the market [4]. - Investors are particularly concerned about the connection between Li Zhe's detention and the premium acquisition, the feasibility of the zero-revenue target meeting its profit commitments, and the source of funding for the company's transformation after four consecutive years of losses [4][5].
市场监管总局公布十起违法广告典型案例,涉及医美、物流等领域
news flash· 2025-07-09 08:28
三、安徽省阜阳市颍东区市场监管局查处安徽全康药业有限公司违法广告案 经查,安徽全康药业有限公司在互联网推广"永邦牌葛根豆蔻片"等保健食品过程中,通过宣称"日产80 万瓶""20余年实力大厂"等与实际情况不符的信息,对消费者造成误导。 今年6月,安徽省阜阳市颍东区市场监管局依据《中华人民共和国广告法》有关规定,对安徽全康药业 有限公司作出罚款21万元的行政处罚。 今年以来,全国市场监管部门持续加大对违法广告的打击力度,防范经营主体借违法广告加剧"内卷 式"竞争,切实维护公平有序的广告市场秩序。截至2025年5月底,全国市场监管部门共查处违法广告案 件14315件,罚没款1.01亿元。现选取一批已办结的违法广告典型案例予以公布。 一、四川省成都市成华区市场监管局查处成都成华韩后医疗美容医院有限公司违法广告案 经查,成都成华韩后医疗美容医院有限公司在以直播电商形式推销"半岛超声炮""欧洲之星全面部全模 式""星耀超光子"等医疗美容项目过程中,宣称的治疗功效与实际情况不符,并使用"单次我们的续航能 力是9—12个月""能够解决肌肤20多种问题"等宣传用语为功效作保证。 今年1月,四川省成都市成华区市场监管局依据《中华 ...
投资深圳 | 一文看懂深圳市高端医疗器械发展现状与投资机会前瞻(附高端医疗器械产业现状、空间布局、投资机会分析等)
Qian Zhan Wang· 2025-07-09 02:12
转自:前瞻产业研究院 1、深圳市高端医疗器械产业政策环境 ——深圳市高端医疗器械产业重点政策梳理 深圳作为中国改革开放的标杆城市,其政策红利的持续释放与创新迭代,使其成为全球投资者不可忽视 的战略高地。深圳从"政策红利"向"产业红利"转型的核心抓手是科技创新,始终以产业需求为导向,推 动产业结构向高端化、智能化跃迁。 作为全球和中国高端医疗器械产业的核心阵地,深圳的政策红利的精准性、系统性和前瞻性,使其成为 资本与技术汇聚的"超级磁场"。 近年来,深圳市出台多项鼓励性政策,不断加大对高端医疗器械产业的支持力度。2024年3月,深圳出 台《关于加快发展新质生产力进一步推进战略性新兴产业集群和未来产业高质量发展的实施方案》,指 出针对具有战略意义、处于风口期、资源投入大的高端医疗器械等7个产业集群,举全市之力集聚资 源,以超常规力度支持培育。 | 时间 | 政策名称 | 内容解读 | | --- | --- | --- | | 2025年4月 | 《深圳市全链条支持医药 和医疗器械发展若干措 | 聚焦高端医学影像、医用机器人、高性能植介入器械、体外诊断、生命监护 | | | | 与支持、人工智能辅助诊断系统等方向 ...
中国海防: 中国海防关于为所属子公司提供担保的进展公告
Zheng Quan Zhi Xing· 2025-07-08 16:07
Core Viewpoint - The company has provided a guarantee of RMB 3 million for its wholly-owned subsidiary, Yichang Yinghan Ultrasonic Electric Co., Ltd., to support its financing needs, with no overdue guarantees reported [1][4]. Group 1: Guarantee Overview - The company signed a guarantee contract with China Shipbuilding Finance Co., Ltd. for the financing of Yinghan Ultrasonic, with a total guarantee amount of RMB 3 million [1][3]. - The company has provided a total guarantee amount of RMB 3 million for Yinghan Ultrasonic as of the announcement date [1][6]. - There are no counter-guarantees associated with this guarantee [1]. Group 2: Subsidiary Information - Yinghan Ultrasonic is a wholly-owned subsidiary of the company, engaged in the design, development, production, sales, installation, and after-sales service of various equipment and systems [2]. Group 3: Financial Status of the Subsidiary - As of March 31, 2025, Yinghan Ultrasonic reported total assets of RMB 219.78 million and total liabilities of RMB 146.50 million, resulting in net assets of RMB 73.28 million [3]. - For the year 2024, the subsidiary's operating income was RMB 210.15 million, with a net profit of RMB 12.12 million, while for the first quarter of 2025, the operating income was RMB 1.98 million, resulting in a net loss of RMB 1.02 million [3]. Group 4: Necessity and Reasonableness of the Guarantee - The guarantee is deemed necessary and reasonable as the company has control over the subsidiary and its current operating status is good, indicating manageable risk [4]. Group 5: Board Approval - The guarantee has been approved by the company's board of directors and is within the limits set by the 2024 annual shareholders' meeting, thus not requiring further approval [6]. Group 6: Total Guarantee Amount - As of the announcement date, the total amount of external guarantees provided by the company is RMB 238.70 million, which accounts for 2.93% of the company's net assets as of December 31, 2024 [6].
政策支持高端医疗器械创新发展 AI、机器人等技术加速临床应用
Zheng Quan Ri Bao· 2025-07-07 16:49
中国信息协会常务理事、国研新经济研究院创始院长朱克力在接受《证券日报》记者采访时表示,《公告》的发布对我国 高端医疗器械领域而言是重大利好,其围绕脑机接口、人工智能、医用机器人等前沿核心技术领域创新,提出了具体要求和方 向,这将有效推动科研成果加速转化为实际产品,更好地满足患者临床需求。 政策利好频出 具体来看,《公告》明确将医用机器人、高端医学影像设备、人工智能医疗器械和新型生物材料医疗器械等视为塑造医疗 器械新质生产力的关键领域,并提出了优化特殊审批程序、完善分类和命名原则、持续健全标准体系、进一步明晰注册审查要 求、健全沟通指导机制和专家咨询机制、细化上市后监管要求、强化上市后质量安全监测、密切跟进产业发展、推进监管科学 研究、推动全球监管协调等措施。 上海杉达学院数字商法研究中心研究助理武于蒙对《证券日报》记者表示,《公告》明确将医用机器人等视为塑造医疗器 械新质生产力的关键领域,给予政策支持,可激发企业在这些前沿技术领域的研发投入积极性,加速技术创新和产品升级。 本报记者 李万晨曦 近日,《国家药监局关于发布优化全生命周期监管支持高端医疗器械创新发展有关举措的公告》发布(以下简称《公 告》),全力支 ...